Mast cell-mediated mechanisms of nociception

International Journal of Molecular Sciences

Volumn 16, Issue 12, 2015, Pages 29069-29092

  Aich, Anupam ^a   Afrin, Lawrence B ^a   Gupta, Kalpna ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Cancer; Cytokines; Hyperalgesia; Inflammation; Mast cells; Migraine; Pain; Sickle cell disease; Substance P; Tryptase

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CETIRIZINE; CORTICOTROPIN RELEASING FACTOR; CROMOGLYCATE DISODIUM; ENDOTHELIN 1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; NERVE GROWTH FACTOR; NEUROKININ 1 RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 2; RANITIDINE; RANTES; SERUM AMYLOID A; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TRANSIENT RECEPTOR POTENTIAL CHANNEL A1; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; UVOMORULIN; VANILLOID RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE; CYTOKINE;

AUTOMUTILATION; CANCER PAIN; CELL INTERACTION; CHRONIC PROSTATITIS; COMPLEX REGIONAL PAIN SYNDROME; CYSTALGIA; ENDOMETRIOSIS; FIBROMYALGIA; HUMAN; HYPERALGESIA; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INFLAMMATION; INFLAMMATORY INFILTRATE; INTERSTITIAL CYSTITIS; IRRITABLE COLON; MAST CELL; MIGRAINE; NERVE CELL NETWORK; NOCICEPTION; NONHUMAN; PAIN; PELVIS PAIN SYNDROME; PROTEIN EXPRESSION; REVIEW; SICKLE CELL ANEMIA; SPINAL GANGLION; VULVODYNIA; ANIMAL; COMPLICATION; IMMUNOLOGY; NEOPLASM; PATHOLOGY;

ANEMIA, SICKLE CELL; ANIMALS; CYTOKINES; HUMANS; HYPERALGESIA; INFLAMMATION; MAST CELLS; MIGRAINE DISORDERS; NEOPLASMS; NOCICEPTION; PAIN;

EID: 84949448574     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161226151     Document Type: Review

References (251)

1. Von Recklinghausen, F. Ueber eiter-und bindegewebskörperchen. Arch. Pathol. Anat. 1863, 28, 157-197.
2. Ehrlich, P. Beitrage fur Theorie und Praxis der Histologischen Farbung; Leipzig University: Leipzig, Germany, 1878.
3. Nettleship, E.; Tay, W. Rare forms of urticaria. Br. Med. J. 1869, 2, 323-324.
4. Sangster, A. An anomalous mottled rash, accompanied by pruritus, factitious urticaria and pigmentation, “urticaria pigmentosa(?)”. Trans. Clin. Soc. 1878, 11, 161-163.
5. Unna, P.G. Beitrage zur anatomie und pathogenese der urticaria simplex und pigmentosa: Zur Kenntnis des elastischen Gewebes der Haut; Voss Leopold: Leipzig, Germany, 1887.
6. Ellis, J. Urticaria pigmentosa: A report of a case with autopsy. Arch. Pathol. 1949, 48, 426-435.
7. Efrati, P.; Klajman, A.; Spitz, H. Mast cell leukemia?—Malignant mastocytosis with leukemia-like manifestations. Blood 1957, 12, 869-882.
8. Holmgren, H., Wilander, O. Beitrag zur kenntnis der chemie und funktion der ehrlichschen mastzellen. Z. Mikrosk. Anat. Forsch 1937, 42, 242-278.
9. Jorpes, E.; Holmgren, H.; Wilander, O. Über das vorkommen von heparin in den gefässwänden und in den augen. Z. Mikrosk. Anat. Forsch 1937, 42, 279-300.
10. Riley, J.F.; West, G.B. Histamine in tissue mast cells. J. Physiol. 1952, 117, 72P-73P.
11. Riley, J.F.; West, G.B. The presence of histamine in tissue mast cells. J. Physiol. 1953, 120, 528-537.
12. Schwartz, L.B.; Metcalfe, D.D.; Miller, J.S.; Earl, H.; Sullivan, T. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N. Engl. J. Med. 1987, 316, 1622-1626.
13. Hallgren, J.; Pejler, G. Biology of mast cell tryptase. An inflammatory mediator. FEBS J. 2006, 273, 1871-1895.
14. Schwartz, L.B.; Sakai, K.; Bradford, T.R.; Ren, S.; Zweiman, B.; Worobec, A.S.; Metcalfe, D.D. The α form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J. Clin. Investig. 1995, 96, 2702-2710.
15. Borer-Reinhold, M.; Haeberli, G.; Bitzenhofer, M.; Jandus, P.; Hausmann, O.; Fricker, M.; Helbling, A.; Muller, U. An increase in serum tryptase even below 11.4 ng/mL may indicate a mast cell-mediated hypersensitivity reaction: A prospective study in hymenoptera venom allergic patients. Clin. Exp. Allergy 2011, 41, 1777-1783.
16. Ibelgufts, H. “Mast cells” in cope: Cytokines and cells online pathfinder encyclopedia. Available online: http://www.copewithcytokines.de/cope.cgi?key=mast%20cells (accessed on 16 October 2015).
17. Grace, P.M.; Hutchinson, M.R.; Maier, S.F.; Watkins, L.R. Pathological pain and the neuroimmune interface. Nat. Rev. Immunol. 2014, 14, 217-231.
18. Héron, A.; Dubayle, D. A focus on mast cells and pain. J. Neuroimmunol. 2013, 264, 1-7.
19. Chatterjea, D.; Martinov, T. Mast cells: Versatile gatekeepers of pain. Mol. Immunol. 2015, 63, 38-44.
20. Theoharides, T.C.; Alysandratos, K.D.; Angelidou, A.; Delivanis, D.A.; Sismanopoulos, N.; Zhang, B.; Asadi, S.; Vasiadi, M.; Weng, Z.; Miniati, A. et al. Mast cells and inflammation. Biochim. Biophys. Acta 2012, 1822, 21-33.
21. Boyce, J.A. The biology of the mast cell. Allergy Asthma Proc. 2004, 25, 27-30.
22. Varatharaj, A.; Mack, J.; Davidson, J.R.; Gutnikov, A.; Squier, W. Mast cells in the human dura: Effects of age and dural bleeding. Childs Nerv. Syst. 2012, 28, 541-545.
23. Gri, G.; Frossi, B.; D’Inca, F.; Danelli, L.; Betto, E.; Mion, F.; Sibilano, R.; Pucillo, C. Mast cell: An emerging partner in immune interaction. Front. Immunol. 2012, 3, 120.
24. Graziottin, A.; Skaper, S.D.; Fusco, M. Mast cells in chronic inflammation, pelvic pain and depression in women. Gynecol. Endocr. 2014, 30, 472-477.
25. Xu, Y.; Chen, G. Mast cell and autoimmune diseases. Mediat. Inflamm. 2015, 2015, 8.
26. Sismanopoulos, N.; Delivanis, D.A.; Alysandratos, K.D.; Angelidou, A.; Therianou, A.; Kalogeromitros, D.; Theoharides, T.C. Mast cells in allergic and inflammatory diseases. Curr. Pharm. Des. 2012, 18, 2261-2277.
27. Tore, F.; Tuncel, N. Mast cells: Target and source of neuropeptides. Curr. Pharm. Des. 2009, 15, 3433-3445.
28. Anand, P.; Singh, B.; Jaggi, A.S.; Singh, N. Mast cells: An expanding pathophysiological role from allergy to other disorders. Naunyn Schmiedebergs Arch. Pharmacol. 2012, 385, 657-670.
29. Kleij, H.P.; Bienenstock, J. Significance of conversation between mast cells and nerves. Allergy Asthma Clin. Immunol. 2005, 1, 65-80.
30. Matsuda, H.; Kawakita, K.; Kiso, Y.; Nakano, T.; Kitamura, Y. Substance P induces granulocyte infiltration through degranulation of mast cells. J. Immunol. 1989, 142, 927-931.
31. Anaf, V.; Chapron, C.; el Nakadi, I.; de Moor, V.; Simonart, T.; Noel, J.C. Pain, mast cells, and nerves in peritoneal, ovarian, and deep infiltrating endometriosis. Fertil. Steril. 2006, 86, 1336-1343.
32. Barbara, G.; Stanghellini, V.; de Giorgio, R.; Cremon, C.; Cottrell, G.S.; Santini, D.; Pasquinelli, G.; Morselli-Labate, A.M.; Grady, E.F.; Bunnett, N.W. et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004, 126, 693-702.
33. Watson, J.J.; Allen, S.J.; Dawbarn, D. Targeting nerve growth factor in pain: What is the therapeutic potential? Bio Drugs 2008, 22, 349-359.
34. Vincent, L.; Vang, D.; Nguyen, J.; Gupta, M.; Luk, K.; Ericson, M.E.; Simone, D.A.; Gupta, K. Mast cell activation contributes to sickle cell pathobiology and pain in mice. Blood 2013, 122, 1853-1862.
35. Levy, D.; Burstein, R.; Kainz, V.; Jakubowski, M.; Strassman, A.M. Mast cell degranulation activates a pain pathway underlying migraine headache. Pain 2007, 130, 166-176.
36. Taiwo, O.B.; Kovács, K.J.; Sun, Y.; Larson, A.A. Unilateral spinal nerve ligation leads to an asymmetrical distribution of mast cells in the thalamus of female but not male mice. Pain 2005, 114, 131-140.
37. Afrin, L.B.; Molderings, G.J. A concise, practical guide to diagnostic assessment for mast cell activation disease. World J. Hematol. 2014, 3, 1-17.
38. Valent, P.; Akin, C.; Arock, M.; Brockow, K.; Butterfield, J.H.; Carter, M.C.; Castells, M.; Escribano, L.; Hartmann, K.; Lieberman, P. et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: A consensus proposal. Int. Arch. Allergy Immunol. 2012, 157, 215-225.
39. Barete, S.; Assous, N.; de Gennes, C.; Grandpeix, C.; Feger, F.; Palmerini, F.; Dubreuil, P.; Arock, M.; Roux, C.; Launay, J.M. et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann. Rheum. Dis. 2010, 69, 1838-1841.
40. Hermine, O.; Lortholary, O.; Leventhal, P.S.; Catteau, A.; Soppelsa, F.; Baude, C.; Cohen-Akenine, A.; Palmérini, F.; Hanssens, K.; Yang, Y. et al. Case-control cohort study of patients’ perceptions of disability in mastocytosis. PLoS ONE 2008, 3, e2266.
41. Jennings, S.; Russell, N.; Jennings, B.; Slee, V.; Sterling, L.; Castells, M.; Valent, P.; Akin, C. The mastocytosis society survey on mast cell disorders: Patient experiences and perceptions. J. Allergy Clin. Immunol. Pract. 2014, 2, 70-76.
42. Molderings, G.J.; Kolck, U.W.; Scheurlen, C.; Bruss, M.; Homann, J.; von Kugelgen, I. Multiple novel alterations in kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder. Scand. J. Gastroenterol. 2007, 42, 1045-1053.
43. Molderings, G.J.; Meis, K.; Kolck, U.W.; Homann, J.; Frieling, T. Comparative analysis of mutation of tyrosine kinase kit in mast cells from patients with systemic mast cell activation syndrome and healthy subjects. Immunogenetics 2010, 62, 721-727.
44. Pardanani, A. How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). Blood 2013, 121, 3085-3094.
45. Chaibi, A.; Tuchin, P.J.; Russell, M.B. Manual therapies for migraine: A systematic review. J. Headache Pain 2011, 12, 127-133.
46. Sicuteri, F. Mast cells and their active substances: Their role in the pathogenesis of migraine. Headache 1963, 3, 86-92.
47. Heatley, R.V.; Denburg, J.A.; Bayer, N.; Bienenstock, J. Increased plasma histamine levels in migraine patients. Clin. Allergy 1982, 12, 145-149.
48. Sjaastad, O.; Sjaastad, O.V. Urinary histamine excretion in migraine and cluster headache. Further observations. J. Neurol. 1977, 216, 91-104.
49. Haimart, M.; Pradalier, A.; Launay, J.M.; Dreux, C.; Dry, J. Whole blood and plasma histamine in common migraine. Cephalalgia 1987, 7, 39-42.
50. Rossi, P.; Fiermonte, G.; Pierelli, F. Cinnarizine in migraine prophylaxis: Efficacy, tolerability and predictive factors for therapeutic responsiveness. An open-label pilot trial. Funct. Neurol. 2003, 18, 155-159.
51. Lewis, D.W.; Diamond, S.; Scott, D.; Jones, V. Prophylactic treatment of pediatric migraine. Headache J. Head Face Pain 2004, 44, 230-237.
52. Togha, M.; Ashrafian, H.; Tajik, P. Open-label trial of cinnarizine in migraine prophylaxis. Headache J. Head Face Pain 2006, 46, 498-502.
53. Lassen, L.H.; Thomsen, L.L.; Olesen, J. Histamine induces migraine via the h1-receptor. Support for the no hypothesis of migraine. Neuroreport 1995, 6, 1475-1479.
54. Hasselblatt, M.; Kohler, J.; Volles, E.; Ehrenreich, H. Simultaneous monitoring of endothelin-1 and vasopressin plasma levels in migraine. Neuroreport 1999, 10, 423-425.
55. Sarchielli, P.; Alberti, A.; Baldi, A.; Coppola, F.; Rossi, C.; Pierguidi, L.; Floridi, A.; Calabresi, P. Proinflammatory cytokines, adhesion molecules, and lymphocyte integrin expression in the internal jugular blood of migraine patients without aura assessed ictally. Headache 2006, 46, 200-207.
56. Sheftell, F.; Rapoport, A.; Weeks, R.; Walker, B.; Gammerman, I.; Baskin, S. Montelukast in the prophylaxis of migraine: A potential role for leukotriene modifiers. Headache 2000, 40, 158-163.
57. Zhang, X.C.; Strassman, A.M.; Burstein, R.; Levy, D. Sensitization and activation of intracranial meningeal nociceptors by mast cell mediators. J. Pharmacol. Exp. Ther. 2007, 322, 806-812.
58. Zhang, X.C.; Levy, D. Modulation of meningeal nociceptors mechanosensitivity by peripheral proteinase-activated receptor-2: The role of mast cells. Cephalalgia 2008, 28, 276-284.
59. Zhang, X.C.; Kainz, V.; Jakubowski, M.; Burstein, R.; Strassman, A.; Levy, D. Localization of COX-1 and COX-2 in the intracranial dura mater of the rat. Neurosci. Lett. 2009, 452, 33-36.
60. Zhang, X.C.; Kainz, V.; Burstein, R.; Levy, D. Tumor necrosis factor-α induces sensitization of meningeal nociceptors mediated via local COX and p38 map kinase actions. Pain 2011, 152, 140-149.
61. Zhang, X.; Burstein, R.; Levy, D. Local action of the proinflammatory cytokines IL-1β and IL-6 on intracranial meningeal nociceptors. Cephalal. Int. J. Headache 2012, 32, 66-72.
62. Yan, J.; Melemedjian, O.K.; Price, T.J.; Dussor, G. Sensitization of dural afferents underlies migraine-related behavior following meningeal application of interleukin-6 (IL-6). Mol. Pain 2012, 8, 1744-8069.
63. Goadsby, P.J.; Edvinsson, L. The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol. 1993, 33, 48-56.
64. Dimtriadou, V.; Buzzi, M.G.; Moskowitz, M.A.; Theoharides, T.C. Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells. Neuroscience 1991, 44, 97-112.
65. Buzzi, M.G.; Dimitriadou, V.; Theoharides, T.C.; Moskowitz, M.A. 5-hydroxytryptamine receptor agonists for the abortive treatment of vascular headaches block mast cell, endothelial and platelet activation within the rat dura mater after trigeminal stimulation. Brain Res. 1992, 583, 137-149.
66. Asghar, M.S.; Hansen, A.E.; Amin, F.M.; van der Geest, R.J.; Koning, P.; Larsson, H.B.; Olesen, J.; Ashina, M. Evidence for a vascular factor in migraine. Ann. Neurol. 2011, 69, 635-645.
67. Dussor, G. Asics as therapeutic targets for migraine. Neuropharmacology 2015, 94, 64-71.
68. Yan, J.; Edelmayer, R.M.; Wei, X.; de Felice, M.; Porreca, F.; Dussor, G. Dural afferents express acid-sensing ion channels: A role for decreased meningeal ph in migraine headache. Pain 2011, 152, 106-113.
69. De Young, M.B.; Nemeth, E.F.; Scarpa, A. Measurement of the internal pH of mast cell granules using microvolumetric fluorescence and isotopic techniques. Arch. Biochem. Biophys. 1987, 254, 222-233.
70. Yan, J.; Wei, X.; Bischoff, C.; Edelmayer, R.M.; Dussor, G. pH-evoked dural afferent signaling is mediated by ASIC3 and is sensitized by mast cell mediators. Headache J. Head Face Pain 2013, 53, 1250-1261.
71. Durham, P.L.; Masterson, C.G. Two mechanisms involved in trigeminal CGRP release: Implications for migraine treatment. Headache J. Head Face Pain 2013, 53, 67-80.
72. Bosch, P.C.; Bosch, D.C. Treating interstitial cystitis/bladder pain syndrome as a chronic disease. Rev. Urol. 2014, 16, 83-87.
73. Moutzouris, D.-A.; Falagas, M.E. Interstitial cystitis: An unsolved enigma. Clin. J. Am. Soc. Nephrol. 2009, 4, 1844-1857.
74. Kastrup, J.; Hald, T.; Larsen, S.; Nielsen, V.G. Histamine content and mast cell count of detrusor muscle in patients with interstitial cystitis and other types of chronic cystitis. Br. J. Urol. 1983, 55, 495-500.
75. Aldenborg, F.; Fall, M.; Enerback, L. Proliferation and transepithelial migration of mucosal mast cells in interstitial cystitis. Immunology 1986, 58, 411-416.
76. Pang, X.; Cotreau-Bibbo, M.M.; Sant, G.R.; Theoharides, T.C. Bladder mast cell expression of high affinity oestrogen receptors in patients with interstitial cystitis. Br. J. Urol. 1995, 75, 154-161.
77. Yamada, T.; Murayama, T.; Mita, H.; Akiyama, K. Subtypes of bladder mast cells in interstitial cystitis. Int. J. Urol. 2000, 7, 292-297.
78. Peeker, R.; Enerback, L.; Fall, M.; Aldenborg, F. Recruitment, distribution and phenotypes of mast cells in interstitial cystitis. J. Urol. 2000, 163, 1009-1015.
79. El-Mansoury, M.; Boucher, W.; Sant, G.R.; Theoharides, T.C. Increased urine histamine and methylhistamine in interstitial cystitis. J. Urol. 1994, 152, 350-353.
80. Boucher, W.; el-Mansoury, M.; Pang, X.; Sant, G.R.; Theoharides, T.C. Elevated mast cell tryptase in the urine of patients with interstitial cystitis. Br. J. Urol. 1995, 76, 94-100.
81. Lotz, M.; Villiger, P.; Hugli, T.; Koziol, J.; Zuraw, B.L. Interleukin-6 and interstitial cystitis. J. Urol. 1994, 152, 869-873.
82. Liu, H.T.; Tyagi, P.; Chancellor, M.B.; Kuo, H.C. Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. BJU Int. 2009, 104, 1476-1481.
83. Jhang, J.F.; Hsu, Y.H.; Kuo, H.C. Possible pathophysiology of ketamine-related cystitis and associated treatment strategies. Int. J. Urol. 2015, 22, 816-825.
84. Theoharides, T.C.; Sant, G.R.; el-Mansoury, M.; Letourneau, R.; Ucci, A.A., Jr.; Meares, E.M., Jr Activation of bladder mast cells in interstitial cystitis: A light and electron microscopic study. J. Urol. 1995, 153, 629-636.
85. Shie, J.H.; Kuo, H.C. Higher levels of cell apoptosis and abnormal e-cadherin expression in the urothelium are associated with inflammation in patients with interstitial cystitis/painful bladder syndrome. BJU Int. 2011, 108, 16.
86. Liu, H.T.; Shie, J.H.; Chen, S.H.; Wang, Y.S.; Kuo, H.C. Differences in mast cell infiltration, e-cadherin, and zonula occludens-1 expression between patients with overactive bladder and interstitial cystitis/bladder pain syndrome. Urology 2012, 80, e213-e218.
87. Bjorling, D.E.; Jerde, T.J.; Zine, M.J.; Busser, B.W.; Saban, M.R.; Saban, R. Mast cells mediate the severity of experimental cystitis in mice. J. Urol 1999, 162, 231-236.
88. Rudick, C.N.; Bryce, P.J.; Guichelaar, L.A.; Berry, R.E.; Klumpp, D.J. Mast cell-derived histamine mediates cystitis pain. PLoS ONE 2008, 3, e0002096.
89. Boudes, M.; Uvin, P.; Kerselaers, S.; Vennekens, R.; Voets, T.; de Ridder, D. Functional characterization of a chronic cyclophosphamide-induced overactive bladder model in mice. Neurourol. Urodyn. 2011, 30, 1659-1665.
90. Liu, W.; Evanoff, D.P.; Chen, X.; Luo, Y. Urinary bladder epithelium antigen induces CD8+ T cell tolerance, activation, and autoimmune response. J. Immunol. 2007, 178, 539-546.
91. Robbins, M.T.; DeBerry, J.; Ness, T.J. Chronic psychological stress enhances nociceptive processing in the urinary bladder in high-anxiety rats. Physiol. Behav. 2007, 91, 544-550.
92. Westropp, J.L.; Buffington, C.A.T. In vivo models of interstitial cystitis. J. Urol. 2002, 167, 694-702.
93. Klumpp, D.J.; Rudick, C.N. Summation model of pelvic pain in interstitial cystitis. Nat. Clin. Pract. Urol. 2008, 5, 494.
94. Li, M.; Yang, K.; Wang, X.; Xu, X.; Zhu, L.; Wang, H. Mast cells infiltration and decreased E-cadherin expression in ketamine-induced cystitis. Toxicol. Rep. 2015, 2, 205-209.
95. Rudick, C.N.; Schaeffer, A.J.; Klumpp, D.J. Pharmacologic attenuation of pelvic pain in a murine model of interstitial cystitis. BMC Urol. 2009, 9, 1471-2490.
96. Chen, M.C.; Keshavan, P.; Gregory, G.D.; Klumpp, D.J. Rantes mediates TNF-dependent lamina propria mast cell accumulation and barrier dysfunction in neurogenic cystitis. Am. J. Physiol. Ren. Physiol. 2007, 292, F1372-F1379.
97. Chen, M.C.; Mudge, C.S.; Klumpp, D.J. Urothelial lesion formation is mediated by TNFR1 during neurogenic cystitis. Am. J. Physiol. Ren. Physiol. 2006, 291, F741-F749.
98. Bicer, F.; Altuntas, C.Z.; Izgi, K.; Ozer, A.; Kavran, M.; Tuohy, V.K.; Daneshgari, F. Chronic pelvic allodynia is mediated by CCL2 through mast cells in an experimental autoimmune cystitis model. Am. J. Physiol. Ren. Physiol. 2015, 308, F103-F113.
99. Lv, J.; Huang, Y.; Zhu, S.; Yang, G.; Zhang, Y.; Leng, J.; Bo, J.; Liu, D. MCP-1-induced histamine release from mast cells is associated with development of interstitial cystitis/bladder pain syndrome in rat models. Mediat. Inflamm. 2012, 2012, 9.
100. Yang, W.; Rudick, C.N.; Hoxha, E.; Allsop, S.A.; Dimitrakoff, J.D.; Klumpp, D.J. Ca2+/calmodulin-dependent protein kinase II is associated with pelvic pain of neurogenic cystitis. Am. J. Physiol. Ren. Physiol. 2012, 303, F350-F356.
101. Murphy, S.F.; Schaeffer, A.J.; Thumbikat, P. Immune mediators of chronic pelvic pain syndrome. Nat. Rev. Urol. 2014, 11, 259-269.
102. Done, J.D.; Rudick, C.N.; Quick, M.L.; Schaeffer, A.J.; Thumbikat, P. Role of mast cells in male chronic pelvic pain. J. Urol. 2012, 187, 1473-1482.
103. Gupta, R.K. Mast cell variations in prostate and urinary bladder. Arch. Pathol. 1970, 89, 302-305.
104. Rivero, V.E.; Iribarren, P.; Riera, C.M. Mast cells in accessory glands of experimentally induced prostatitis in male wistar rats. Clin. Immunol. Immunopathol. 1995, 74, 236-242.
105. Schwartz, E.S.; Xie, A.; La, J.H.; Gebhart, G.F. Nociceptive and inflammatory mediator upregulation in a mouse model of chronic prostatitis. Pain 2015, 156, 1537-1544.
106. Watanabe, T.; Inoue, M.; Sasaki, K.; Araki, M.; Uehara, S.; Monden, K.; Saika, T.; Nasu, Y.; Kumon, H.; Chancellor, M.B. Nerve growth factor level in the prostatic fluid of patients with chronic prostatitis/chronic pelvic pain syndrome is correlated with symptom severity and response to treatment. BJU Int. 2011, 108, 248-251.
107. Roman, K.; Done, J.D.; Schaeffer, A.J.; Murphy, S.F.; Thumbikat, P. Tryptase-par2 axis in experimental autoimmune prostatitis, a model for chronic pelvic pain syndrome. Pain 2014, 155, 1328-1338.
108. Quick, M.L.; Mukherjee, S.; Rudick, C.N.; Done, J.D.; Schaeffer, A.J.; Thumbikat, P. CCL2 and CCL3 are essential mediators of pelvic pain in experimental autoimmune prostatitis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2012, 303, R580-R589.
109. National Guideline, C. The Initial Management of Chronic Pelvic Pain. Available online: http://www. guideline.gov/content.aspx?id=37221 (accessed on 10 December 2015).
110. Perry, C.P. Current concepts of pelvic congestion and chronic pelvic pain. J. Soc. Laparoendosc. Surg. 2001, 5, 105-110.
111. Konno, R.; Yamada-Okabe, H.; Fujiwara, H.; Uchiide, I.; Shibahara, H.; Okwada, M.; Ihara, T.; Sugamata, M.; Suzuki, M. Role of immunoreactions and mast cells in pathogenesis of human endometriosis-morphologic study and gene expression analysis. Hum. Cell. 2003, 16, 141-149.
112. Fujiwara, H.; Konno, R.; Netsu, S.; Sugamata, M.; Shibahara, H.; Ohwada, M.; Suzuki, M. Localization of mast cells in endometrial cysts. Am. J. Reprod. Immunol. 2004, 51, 341-344.
113. Paula, R., Jr; Oliani, A.; Vaz-Oliani, D.M.; D’Ávila, S.G.P.; Oliani, S.; Gil, C. The intricate role of mast cell proteases and the annexin A1-FPR1 system in abdominal wall endometriosis. J. Mol. Hist. 2015, 46, 33-43.
114. Kempuraj, D.; Papadopoulou, N.; Stanford, E.J.; Christodoulou, S.; Madhappan, B.; Sant, G.R.; Solage, K.; Adams, T.; Theoharides, T.C. Increased numbers of activated mast cells in endometriosis lesions positive for corticotropin-releasing hormone and urocortin. Am. J. Reprod. Immunol. 2004, 52, 267-275.
115. Sugamata, M.; Ihara, T.; Uchiide, I. Increase of activated mast cells in human endometriosis. Am. J. Reprod. Immunol. 2005, 53, 120-125.
116. Matsuzaki, S.; Canis, M.; Darcha, C.; Fukaya, T.; Yajima, A.; Bruhat, M.A. Increased mast cell density in peritoneal endometriosis compared with eutopic endometrium with endometriosis. Am. J. Reprod. Immunol. 1998, 40, 291-294.
117. Osuga, Y.; Koga, K.; Tsutsumi, O.; Igarashi, T.; Okagaki, R.; Takai, Y.; Matsumi, H.; Hiroi, H.; Fujiwara, T.; Momoeda, M. et al. Stem cell factor (SCF) concentrations in peritoneal fluid of women with or without endometriosis. Am. J. Reprod. Immunol. 2000, 44, 231-235.
118. Arici, A.; Oral, E.; Attar, E.; Tazuke, S.I.; Olive, D.L. Monocyte chemotactic protein-1 concentration in peritoneal fluid of women with endometriosis and its modulation of expression in mesothelial cells. Fertil. Steril. 1997, 67, 1065-1072.
119. Eisermann, J.; Gast, M.J.; Pineda, J.; Odem, R.R.; Collins, J.L. Tumor necrosis factor in peritoneal fluid of women undergoing laparoscopic surgery. Fertil. Steril. 1988, 50, 573-579.
120. Khorram, O.; Taylor, R.N.; Ryan, I.P.; Schall, T.J.; Landers, D.V. Peritoneal fluid concentrations of the cytokine rantes correlate with the severity of endometriosis. Am. J. Obstet. Gynecol. 1993, 169, 1545-1549.
121. Ryan, I.P.; Tseng, J.F.; Schriock, E.D.; Khorram, O.; Landers, D.V.; Taylor, R.N. Interleukin-8 concentrations are elevated in peritoneal fluid of women with endometriosis. Fertil. Steril. 1995, 63, 929-932.
122. Xavier, P.; Belo, L.; Beires, J.; Rebelo, I.; Martinez-de-Oliveira, J.; Lunet, N.; Barros, H. Serum levels of VEGF and TNF-α and their association with c-reactive protein in patients with endometriosis. Arch. Gynecol. Obstet. 2006, 273, 227-231.
123. Hayashi, C.; Chishima, F.; Sugitani, M.; Ichikawa, G.; Nakazawa-Watanabe, T.; Sugita, K.; Suzuki, M.; Nemoto, N.; Yamamoto, T. Relationship between toll-like receptor-4 and MPGES-1 gene expression in local lesions of endometriosis patients. Am. J. Reprod. Immunol. 2013, 69, 231-239.
124. Uchiide, I.; Ihara, T.; Sugamata, M. Pathological evaluation of the rat endometriosis model. Fertil. Steril. 2002, 78, 782-786.
125. Ihara, T.; Uchiide, I.; Sugamata, M. Light and electron microscopic evaluation of antileukotriene therapy for experimental rat endometriosis. Fertil. Steril. 2004, 1, 819-823.
126. McKinnon, B.D.; Evers, J.; Bersinger, N.A.; Mueller, M.D. Induction of the neurokinin 1 receptor by TNFα in endometriotic tissue provides the potential for neurogenic control over endometriotic lesion growth. J. Clin. Endocrinol. Metabol. 2013, 98, 2469-2477.
127. Tokushige, N.; Markham, R.; Russell, P.; Fraser, I.S. Nerve fibres in peritoneal endometriosis. Hum. Reprod. 2006, 21, 3001-3007.
128. Wang, G.; Tokushige, N.; Russell, P.; Dubinovsky, S.; Markham, R.; Fraser, I.S. Hyperinnervation in intestinal deep infiltrating endometriosis. J. Minim. Invasive Gynecol. 2009, 16, 713-719.
129. Kirchhoff, D.; Kaulfuss, S.; Fuhrmann, U.; Maurer, M.; Zollner, T.M. Mast cells in endometriosis: Guilty or innocent bystanders? Expert Opin. Ther. Targets 2012, 16, 237-241.
130. Laux-Biehlmann, A.; d’Hooghe, T.; Zollner, T.M. Menstruation pulls the trigger for inflammation and pain in endometriosis. Trends Pharmacol. Sci. 2015, 36, 270-276.
131. Rocha, M.G.; Silva, J.C.R.E.; Ribeiro da Silva, A.; Candido Dos Reis, F.J.; Nogueira, A.A.; Poli-Neto, O.B. TRPV1 expression on peritoneal endometriosis foci is associated with chronic pelvic pain. Reprod. Sci. 2011, 18, 511-515.
132. Bulun, S.E.; Fang, Z.; Imir, G.; Gurates, B.; Tamura, M.; Yilmaz, B.; Langoi, D.; Amin, S.; Yang, S.; Deb, S. Aromatase and endometriosis. Semin. Reprod. Med. 2004, 22, 45-50.
133. Zaitsu, M.; Narita, S.; Lambert, K.C.; Grady, J.J.; Estes, D.M.; Curran, E.M.; Brooks, E.G.; Watson, C.S.; Goldblum, R.M.; Midoro-Horiuti, T. Estradiol activates mast cells via a non-genomic estrogen receptor-α and calcium influx. Mol. Immunol. 2007, 44, 1977-1985.
134. Guilarte, M.; Santos, J.; de Torres, I.; Alonso, C.; Vicario, M.; Ramos, L.; Martínez, C.; Casellas, F.; Saperas, E.; Malagelada, J.R. Diarrhoea-predominant ibs patients show mast cell activation and hyperplasia in the jejunum. Gut 2007, 56, 203-209.
135. Wang, S.H.; Dong, L.; Luo, J.Y.; Gong, J.; Li, L.; Lu, X.L.; Han, S.P. Decreased expression of serotonin in the jejunum and increased numbers of mast cells in the terminal ileum in patients with irritable bowel syndrome. World J. Gastroenterol. 2007, 13, 6041-6047.
136. Weston, A.P.; Biddle, W.L.; Bhatia, P.S.; Miner, P.B., Jr Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig. Dis. Sci. 1993, 38, 1590-1595.
137. Goral, V.; Kucukoner, M.; Buyukbayram, H. Mast cells count and serum cytokine levels in patients with irritable bowel syndrome. Hepatogastroenterology 2010, 57, 751-754.
138. O’Sullivan, M.; Clayton, N.; Breslin, N.P.; Harman, I.; Bountra, C.; McLaren, A.; O’Morain, C.A. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol. Motil. 2000, 12, 449-457.
139. Park, J.H.; Rhee, P.L.; Kim, H.S.; Lee, J.H.; Kim, Y.H.; Kim, J.J.; Rhee, J.C. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J. Gastroenterol. Hepatol. 2006, 21, 71-78.
140. Di Nardo, G.; Barbara, G.; Cucchiara, S.; Cremon, C.; Shulman, R.J.; Isoldi, S.; Zecchi, L.; Drago, L.; Oliva, S.; Saulle, R. et al. Neuroimmune interactions at different intestinal sites are related to abdominal pain symptoms in children with IBS. Neurogastroenterol. Motil. 2014, 26, 196-204.
141. Vivinus-Nebot, M.; Dainese, R.; Anty, R.; Saint-Paul, M.C.; Nano, J.L.; Gonthier, N.; Marjoux, S.; Frin-Mathy, G.; Bernard, G.; Hebuterne, X. et al. Combination of allergic factors can worsen diarrheic irritable bowel syndrome: Role of barrier defects and mast cells. Am. J. Gastroenterol. 2012, 107, 75-81.
142. Sohn, W.; Lee, O.Y.; Lee, S.P.; Lee, K.N.; Jun, D.W.; Lee, H.L.; Yoon, B.C.; Choi, H.S.; Sim, J.; Jang, K.S. Mast cell number, substance p and vasoactive intestinal peptide in irritable bowel syndrome with diarrhea. Scand. J. Gastroenterol. 2014, 49, 43-51.
143. Barbara, G.; Wang, B.; Stanghellini, V.; de Giorgio, R.; Cremon, C.; di Nardo, G.; Trevisani, M.; Campi, B.; Geppetti, P.; Tonini, M. et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007, 132, 26-37.
144. Song, J.; Zhang, L.; Bai, T.; Qian, W.; Li, R.; Hou, X. Mast cell-dependent mesenteric afferent activation by mucosal supernatant from different bowel segments of guinea pigs with post-infectious irritable bowel syndrome. J. Neurogastroenterol. Motil. 2015, 21, 236-246.
145. Buhner, S.; Li, Q.; Vignali, S.; Barbara, G.; de Giorgio, R.; Stanghellini, V.; Cremon, C.; Zeller, F.; Langer, R.; Daniel, H. et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 2009, 137, 1425-1434.
146. Frieling, T.; Meis, K.; Kolck, U.W.; Homann, J.; Hulsdonk, A.; Haars, U.; Hertfelder, H.J.; Oldenburg, J.; Seidel, H.; Molderings, G.J. Evidence for mast cell activation in patients with therapy-resistant irritable bowel syndrome. Z. Gastroenterol. 2011, 49, 191-194.
147. Klooker, T.K.; Braak, B.; Koopman, K.E.; Welting, O.; Wouters, M.M.; van der Heide, S.; Schemann, M.; Bischoff, S.C.; van den Wijngaard, R.M.; Boeckxstaens, G.E. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010, 59, 1213-1221.
148. Stefanini, G.F.; Saggioro, A.; Alvisi, V.; Angelini, G.; Capurso, L.; di Lorenzo, G.; Dobrilla, G.; Dodero, M.; Galimberti, M.; Gasbarrini, G. et al. Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients. Scand. J. Gastroenterol. 1995, 30, 535-541.
149. Zhou, Q.; Zhang, B.; Verne, N.G. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain 2009, 146, 41-46.
150. Shulman, R.J.; Eakin, M.N.; Czyzewski, D.I.; Jarrett, M.; Ou, C.N. Increased gastrointestinal permeability and gut inflammation in children with functional abdominal pain and irritable bowel syndrome. J. Pediatr. 2008, 153, 646-650.
151. Piche, T.; Barbara, G.; Aubert, P.; Bruley des Varannes, S.; Dainese, R.; Nano, J.L.; Cremon, C.; Stanghellini, V.; de Giorgio, R.; Galmiche, J.P. et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: Involvement of soluble mediators. Gut 2009, 58, 196-201.
152. Cenac, N.; Andrews, C.N.; Holzhausen, M.; Chapman, K.; Cottrell, G.; Andrade-Gordon, P.; Steinhoff, M.; Barbara, G.; Beck, P.; Bunnett, N.W. et al. Role for protease activity in visceral pain in irritable bowel syndrome. J. Clin. Investig. 2007, 117, 636-647.
153. Gecse, K.; Róka, R.; Ferrier, L.; Leveque, M.; Eutamene, H.; Cartier, C.; Ait-Belgnaoui, A.; Rosztóczy, A.; Izbéki, F.; Fioramonti, J. et al. Increased faecal serine protease activity in diarrhoeic ibs patients: A colonic lumenal factor impairing colonic permeability and sensitivity. Gut 2008, 57, 591-599.
154. Akbar, A.; Yiangou, Y.; Facer, P.; Walters, J.R.F.; Anand, P.; Ghosh, S. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut 2008, 57, 923-929.
155. Ford, A.C.; Brandt, L.J.; Young, C.; Chey, W.D.; Foxx-Orenstein, A.E.; Moayyedi, P. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: Systematic review and meta-analysis. Am. J. Gastroenterol. 2009, 104, 1831-1843.
156. Cremon, C.; Carini, G.; Wang, B.; Vasina, V.; Cogliandro, R.F.; de Giorgio, R.; Stanghellini, V.; Grundy, D.; Tonini, M.; de Ponti, F. et al. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am. J. Gastroenterol. 2011, 106, 1290-1298.
157. Jardí, F.; Fernández-Blanco, J.A.; Martínez, V.; Vergara, P. Plasticity of dorsal root ganglion neurons in a rat model of post-infectious gut dysfunction: Potential implication of nerve growth factor. Scand. J. Gastroenterol. 2014, 49, 1296-1303.
158. Barreau, F.; Salvador-Cartier, C.; Houdeau, E.; Bueno, L.; Fioramonti, J. Long-term alterations of colonic nerve-mast cell interactions induced by neonatal maternal deprivation in rats. Gut 2008, 57, 582-590.
159. Barreau, F.; Cartier, C.; Ferrier, L.; Fioramonti, J.; Bueno, L. Nerve growth factor mediates alterations of colonic sensitivity and mucosal barrier induced by neonatal stress in rats. Gastroenterology 2004, 127, 524-534.
160. Dothel, G.; Barbaro, M.R.; Boudin, H.; Vasina, V.; Cremon, C.; Gargano, L.; Bellacosa, L.; de Giorgio, R.; le Berre-Scoul, C.; Aubert, P. et al. Nerve fiber outgrowth is increased in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology 2015, 148, 1002-1011.
161. Moyal-Barracco, M.; Lynch, P.J. 2003 ISSVD terminology and classification of vulvodynia: A historical perspective. J. Reprod. Med. 2004, 49, 772-777.
162. Bohm-Starke, N.; Hilliges, M.; Brodda-Jansen, G.; Rylander, E.; Torebjork, E. Psychophysical evidence of nociceptor sensitization in vulvar vestibulitis syndrome. Pain 2001, 94, 177-183.
163. Bornstein, J.; Goldschmid, N.; Sabo, E. Hyperinnervation and mast cell activation may be used as histopathologic diagnostic criteria for vulvar vestibulitis. Gynecol. Obstet. Investig. 2004, 58, 171-178.
164. Bornstein, J.; Cohen, Y.; Zarfati, D.; Sela, S.; Ophir, E. Involvement of heparanase in the pathogenesis of localized vulvodynia. Int. J. Gynecol. Pathol. 2008, 27, 136-141.
165. Goetsch, M.F.; Morgan, T.K.; Korcheva, V.B.; Li, H.; Peters, D.; Leclair, C.M. Histologic and receptor analysis of primary and secondary vestibulodynia and controls: A prospective study. Am. J. Obstet. Gynecol. 2010, 202, 28.
166. Martinov, T.; Glenn-Finer, R.; Burley, S.; Tonc, E.; Balsells, E.; Ashbaugh, A.; Swanson, L.; Daughters, R.S.; Chatterjea, D. Contact hypersensitivity to oxazolone provokes vulvar mechanical hyperalgesia in mice. PLoS ONE 2013, 8, e78673.
167. Harlow, B.L.; He, W.; Nguyen, R.H.N. Allergic reactions and risk of vulvodynia. Ann. Epidemiol. 2009, 19, 771-777.
168. Schlereth, T.; Birklein, F. Mast cells: Source of inflammation in complex regional pain syndrome? Anesthesiology 2012, 116, 756-757.
169. Heijmans-Antonissen, C.; Wesseldijk, F.; Munnikes, R.J.M.; Huygen, F.J.P.M.; van der Meijden, P.; Hop, W.C.J.; Hooijkaas, H.; Zijlstra, F.J. Multiplex bead array assay for detection of 25 soluble cytokines in blister fluid of patients with complex regional pain syndrome type 1. Mediat. Inflamm. 2006, 2006, 28398.
170. Parkitny, L.; McAuley, J.H.; di Pietro, F.; Stanton, T.R.; O’Connell, N.E.; Marinus, J.; van Hilten, J.J.; Moseley, G.L. Inflammation in complex regional pain syndrome: A systematic review and meta-analysis. Neurology 2013, 80, 106-117.
171. Leis, S.; Weber, M.; Isselmann, A.; Schmelz, M.; Birklein, F. Substance-P-induced protein extravasation is bilaterally increased in complex regional pain syndrome. Exp. Neurol. 2003, 183, 197-204.
172. Dirckx, M.; Groeneweg, G.; van Daele, P.L.A.; Stronks, D.L.; Huygen, F.J.P.M. Mast cells: A new target in the treatment of complex regional pain syndrome? Pain Pract. 2013, 13, 599-603.
173. Huygen, F.J.; Ramdhani, N.; van Toorenenbergen, A.; Klein, J.; Zijlstra, F.J. Mast cells are involved in inflammatory reactions during complex regional pain syndrome type 1. Immunol. Lett. 2004, 91, 147-154.
174. Birklein, F.; Drummond, P.D.; Li, W.; Schlereth, T.; Albrecht, N.; Finch, P.M.; Dawson, L.F.; Clark, J.D.; Kingery, W.S. Activation of cutaneous immune responses in complex regional pain syndrome. J. Pain 2014, 15, 485-495.
175. Sabsovich, I.; Guo, T.Z.; Wei, T.; Zhao, R.; Li, X.; Clark, D.J.; Geis, C.; Sommer, C.; Kingery, W.S. TNF signaling contributes to the development of nociceptive sensitization in a tibia fracture model of complex regional pain syndrome type I. Pain 2008, 137, 507-519.
176. Sabsovich, I.; Wei, T.; Guo, T.Z.; Zhao, R.; Shi, X.; Li, X.; Yeomans, D.C.; Klyukinov, M.; Kingery, W.S.; Clark, J.D. Effect of anti-ngf antibodies in a rat tibia fracture model of complex regional pain syndrome type I. Pain 2008, 138, 47-60.
177. Li, W.W.; Guo, T.Z.; Liang, D.; Shi, X.; Wei, T.; Kingery, W.S.; Clark, J.D. The NALP1 inflammasome controls cytokine production and nociception in a rat fracture model of complex regional pain syndrome. Pain 2009, 147, 277-286.
178. Li, W.W.; Sabsovich, I.; Guo, T.Z.; Zhao, R.; Kingery, W.S.; Clark, J.D. The role of enhanced cutaneous IL-1β signaling in a rat tibia fracture model of complex regional pain syndrome. Pain 2009, 144, 303-313.
179. Wei, T.; Sabsovich, I.; Guo, T.Z.; Shi, X.; Zhao, R.; Li, W.; Geis, C.; Sommer, C.; Kingery, W.S.; Clark, D.J. Pentoxifylline attenuates nociceptive sensitization and cytokine expression in a tibia fracture rat model of complex regional pain syndrome. Eur. J. Pain 2009, 13, 253-262.
180. Li, W.W.; Guo, T.Z.; Li, X.Q.; Kingery, W.S.; Clark, J.D. Fracture induces keratinocyte activation, proliferation, and expression of pro-nociceptive inflammatory mediators. Pain 2010, 151, 843-852.
181. Wei, T.; Li, W.W.; Guo, T.Z.; Zhao, R.; Wang, L.; Clark, D.J.; Oaklander, A.L.; Schmelz, M.; Kingery, W.S. Post-junctional facilitation of substance P signaling in a tibia fracture rat model of complex regional pain syndrome type I. Pain 2009, 144, 278-286.
182. Guo, T.Z.; Offley, S.C.; Boyd, E.A.; Jacobs, C.R.; Kingery, W.S. Substance p signaling contributes to the vascular and nociceptive abnormalities observed in a tibial fracture rat model of complex regional pain syndrome type I. Pain 2004, 108, 95-107.
183. Li, W.W.; Guo, T.Z.; Liang, D.Y.; Sun, Y.; Kingery, W.S.; Clark, J.D. Substance p signaling controls mast cell activation, degranulation, and nociceptive sensitization in a rat fracture model of complex regional pain syndrome. Anesthesiology 2012, 116, 882-895.
184. Martinov, T.; Mack, M.; Sykes, A.; Chatterjea, D. Measuring changes in tactile sensitivity in the hind paw of mice using an electronic von frey apparatus. J. Vis. Exp. 2013, 19, 51212.
185. De Toni, L.G.B.; Menaldo, D.L.; Cintra, A.C.O.; Figueiredo, M.J.; de Souza, A.R.; Maximiano, W.M.A.; Jamur, M.C.; Souza, G.E.P.; Sampaio, S.V. Inflammatory mediators involved in the paw edema and hyperalgesia induced by batroxase, a metalloproteinase isolated from bothrops atrox snake venom. Int. Immunopharmacol. 2015, 28, 199-207.
186. Liu, T.; Bai, Z.T.; Pang, X.Y.; Chai, Z.F.; Jiang, F.; Ji, Y.H. Degranulation of mast cells and histamine release involved in rat pain-related behaviors and edema induced by scorpion buthus martensi karch venom. Eur. J. Pharmacol. 2007, 575, 46-56.
187. Bonavita, A.G.; da Costa, A.S.; Pires, A.L.; Neves-Ferreira, A.G.; Perales, J.; Cordeiro, R.S.; Martins, M.A.; Silva, P.M. Contribution of mast cells and snake venom metalloproteinases to the hyperalgesia induced by bothrops jararaca venom in rats. Toxicon 2006, 47, 885-893.
188. Bai, Z.T.; Chen, B.; Zhang, X.Y.; Fan, G.L.; Ji, Y.H. C-fos expression in rat spinal cord induced by scorpion bmk venom via plantar subcutaneous injection. Neurosci. Res. 2002, 44, 447-454.
189. Ji, Y.H.; Liu, T. The study of sodium channels involved in pain responses using specific modulators. Sheng Li Xue Bao 2008, 60, 628-634.
190. Chen, J.; Tan, Z.Y.; Zhao, R.; Feng, X.H.; Shi, J.; Ji, Y.H. The modulation effects of BMK I, an α-like scorpion neurotoxin, on voltage-gated Na+ currents in rat dorsal root ganglion neurons. Neurosci. Lett. 2005, 390, 66-71.
191. Ye, J.G.; Wang, C.Y.; Li, Y.J.; Tan, Z.Y.; Yan, Y.P.; Li, C.; Chen, J.; Ji, Y.H. Purification, cdna cloning and function assessment of Bmk abT, a unique component from the old world scorpion species. FEBS Lett. 2000, 479, 136-140.
192. Chen, B.; Ji, Y. Antihyperalgesia effect of BMK as, a scorpion toxin, in rat by intraplantar injection. Brain Res. 2002, 952, 322-326.
193. Wang, C.Y.; Tan, Z.Y.; Chen, B.; Zhao, Z.Q.; Ji, Y.H. Antihyperalgesia effect of Bmk IT2, a depressant insect-selective scorpion toxin in rat by peripheral administration. Brain Res. Bull. 2000, 53, 335-338.
194. Chen, J.; Feng, X.H.; Shi, J.; Tan, Z.Y.; Bai, Z.T.; Liu, T.; Ji, Y.H. The anti-nociceptive effect of bmk as, a scorpion active polypeptide, and the possible mechanism on specifically modulating voltage-gated Na+ currents in primary afferent neurons. Peptides 2006, 27, 2182-2192.
195. Tan, Z.Y.; Mao, X.; Xiao, H.; Zhao, Z.Q.; Ji, Y.H. Buthus martensi karsch agonist of skeletal-muscle RYR-1, a scorpion active polypeptide: Antinociceptive effect on rat peripheral nervous system and spinal cord, and inhibition of voltage-gated Na+ currents in dorsal root ganglion neurons. Neurosci. Lett. 2001, 297, 65-68.
196. Tan, Z.Y.; Xiao, H.; Mao, X.; Wang, C.Y.; Zhao, Z.Q.; Ji, Y.H. The inhibitory effects of BMK IT2, a scorpion neurotoxin on rat nociceptive flexion reflex and a possible mechanism for modulating voltage-gated Na+ channels. Neuropharmacology 2001, 40, 352-357.
197. Bai, Z.T.; Liu, T.; Pang, X.Y.; Chai, Z.F.; Ji, Y.H. Suppression by intrathecal BMK IT2 on rat spontaneous pain behaviors and spinal c-Fos expression induced by formalin. Brain Res. Bull. 2007, 73, 248-253.
198. Zhang, X.Y.; Bai, Z.T.; Chai, Z.F.; Zhang, J.W.; Liu, Y.; Ji, Y.H. Suppressive effects of BMK IT2 on nociceptive behavior and C-Fos expression in spinal cord induced by formalin. J. Neurosci Res. 2003, 74, 167-173.
199. Liu, T.; Pang, X.Y.; Jiang, F.; Bai, Z.T.; Ji, Y.H. Anti-nociceptive effects induced by intrathecal injection of bmk as, a polypeptide from the venom of chinese-scorpion buthus martensi karsch, in rat formalin test. J. Ethnopharmacol. 2008, 117, 332-338.
200. Bernstein, C.; Marcus, D. Fibromyalgia: Current concepts in diagnosis, pathogenesis, and treatment. Pain Med. News 2008, 6, 8-19.
201. Wolfe, F.; Smythe, H.A.; Yunus, M.B.; Bennett, R.M.; Bombardier, C.; Goldenberg, D.L.; Tugwell, P.; Campbell, S.M.; Abeles, M.; Clark, P. The american college of rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum. 1990, 33, 160-172.
202. Van Houdenhove, B.; Egle, U.T. Fibromyalgia: A stress disorder? Psychother. Psychosom. 2004, 73, 267-275.
203. Enestrom, S.; Bengtsson, A.; Frodin, T. Dermal IgG deposits and increase of mast cells in patients with fibromyalgia—Relevant findings or epiphenomena? Scand. J. Rheumatol. 1997, 26, 308-313.
204. Blanco, I.; Beritze, N.; Arguelles, M.; Carcaba, V.; Fernandez, F.; Janciauskiene, S.; Oikonomopoulou, K.; de Serres, F.J.; Fernandez-Bustillo, E.; Hollenberg, M.D. Abnormal overexpression of mastocytes in skin biopsies of fibromyalgia patients. Clin. Rheumatol. 2010, 29, 1403-1412.
205. Lucas, H.J.; Brauch, C.M.; Settas, L.; Theoharides, T.C. Fibromyalgia—New concepts of pathogenesis and treatment. Int. J. Immunopathol. Pharmacol. 2006, 19, 5-10.
206. Zhang, Z.; Cherryholmes, G.; Mao, A.; Marek, C.; Longmate, J.; Kalos, M.; Amand, R.P.S.; Shively, J.E. High plasma levels of MCP-1 and eotaxin provide evidence for an immunological basis of fibromyalgia. Exp. Biol. Med. 2008, 233, 1171-1180.
207. Ang, D.C.; Hilligoss, J.; Stump, T. Mast cell stabilizer (ketotifen) in fibromyalgia: Phase 1 randomized controlled clinical trial. Clin. J. Pain 2014, 3, 3.
208. Theoharides, T.C.; Donelan, J.M.; Papadopoulou, N.; Cao, J.; Kempuraj, D.; Conti, P. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol. Sci. 2004, 25, 563-568.
209. Cao, J.; Papadopoulou, N.; Kempuraj, D.; Boucher, W.S.; Sugimoto, K.; Cetrulo, C.L.; Theoharides, T.C. Human mast cells express corticotropin-releasing hormone (CRH) receptors and crh leads to selective secretion of vascular endothelial growth factor. J. Immunol. 2005, 174, 7665-7675.
210. Schwarz, M.J.; Spath, M.; Muller-Bardorff, H.; Pongratz, D.E.; Bondy, B.; Ackenheil, M. Relationship of substance P, 5-hydroxyindole acetic acid and tryptophan in serum of fibromyalgia patients. Neurosci. Lett. 1999, 259, 196-198.
211. Ferraccioli, G.; Cavalieri, F.; Salaffi, F.; Fontana, S.; Scita, F.; Nolli, M.; Maestri, D. Neuroendocrinologic findings in primary fibromyalgia (soft tissue chronic pain syndrome) and in other chronic rheumatic conditions (rheumatoid arthritis, low back pain). J. Rheumatol. 1990, 17, 869-873.
212. Griep, E.N.; Boersma, J.W.; de Kloet, E. Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome. J. Rheumatol. 1993, 20, 469-474.
213. McCain, G.; Tilbe, K. Diurnal hormone variation in fibromyalgia syndrome: A comparison with rheumatoid arthritis. J. Rheumatol. Suppl. 1989, 19, 154-157.
214. Riedel, W.; Layka, H.; Neeck, G. Secretory pattern of GH, TSH, thyroid hormones, ACTH, cortisol, FSH, and LH in patients with fibromyalgia syndrome following systemic injection of the relevant hypothalamic-releasing hormones. Z. Rheumatol. 1998, 57, S81-S87.
215. Symons, F.J. Self-injurious behavior in neurodevelopmental disorders: Relevance of nociceptive and immune mechanisms. Neurosci. Biobehav. Rev. 2011, 35, 1266-1274.
216. Rao, K.N.; Sudarshan, C.Y.; Begum, S. Self-injurious behavior: A clinical appraisal. Indian J. Psychiatry 2008, 50, 288-297.
217. Symons, F.J.; Wendelschafer-Crabb, G.; Kennedy, W.; Heeth, W.; Bodfish, J.W. Degranulated mast cells in the skin of adults with self-injurious behavior and neurodevelopmental disorders. Brain Behav. Immun. 2009, 23, 365-370.
218. Symons, F.J.; Wendelschafer-Crabb, G.; Kennedy, W.; Hardrict, R.; Dahl, N.; Bodfish, J.W. Evidence of altered epidermal nerve fiber morphology in adults with self-injurious behavior and neurodevelopmental disorders. Pain 2008, 134, 232-237.
219. Symons, F.J.; Tervo, R.C.; Barney, C.C.; Damerow, J.; Selim, M.; McAdams, B.; Foster, S.; Crabb, G.W.; Kennedy, W. Peripheral innervation in children with global developmental delay: Biomarker for risk for self-injurious behavior? J. Child Neurol. 2015, 30, 1722-1727.
220. Symons, F.J.; Gilles, E.; Tervo, R.; Wendelschafer-Crabb, G.; Panoutsopoulou, I.; Kennedy, W. Skin and self-injury: A possible link between peripheral innervation and immune function? Dev. Med. Child Neurol. 2015, 57, 677-680.
221. Manchanda, R.K.; Jaggi, A.S.; Singh, N. Ameliorative potential of sodium cromoglycate and diethyldithiocarbamic acid in restraint stress-induced behavioral alterations in rats. Pharmacol. Rep. 2011, 63, 54-63.
222. Van den Beuken-van Everdingen, M.H.; de Rijke, J.M.; Kessels, A.G.; Schouten, H.C.; van Kleef, M.; Patijn, J. Prevalence of pain in patients with cancer: A systematic review of the past 40 years. Ann. Oncol. 2007, 18, 1437-1449.
223. Magnon, C.; Hall, S.J.; Lin, J.; Xue, X.; Gerber, L.; Freedland, S.J.; Frenette, P.S. Autonomic nerve development contributes to prostate cancer progression. Science 2013, 341, 1236361.
224. Garcia-Recio, S.; Fuster, G.; Fernandez-Nogueira, P.; Pastor-Arroyo, E.M.; Park, S.Y.; Mayordomo, C.; Ametller, E.; Mancino, M.; Gonzalez-Farre, X.; Russnes, H.G. Substance p autocrine signaling contributes to persistent her2 activation that drives malignant progression and drug resistance in breast cancer. Cancer Res. 2013, 73, 6424-6434.
225. Boehncke, S.; Hardt, K.; Schadendorf, D.; Henschler, R.; Boehncke, W.H.; Duthey, B. Endogenous μ-opioid peptides modulate immune response towards malignant melanoma. Exp. Dermatol. 2011, 20, 24-28.
226. Zylla, D.; Kuskowski, M.A.; Gupta, K.; Gupta, P. Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer. Br. J. Anaesth. 2014, 10, doi:10.1093/bja/aeu351.
227. Zylla, D.; Gourley, B.L.; Vang, D.; Jackson, S.; Boatman, S.; Lindgren, B.; Kuskowski, M.A.; Le, C.; Gupta, K.; Gupta, P. Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer 2013, 119, 4103-4110.
228. Cai, S.W.; Yang, S.Z.; Gao, J.; Pan, K.; Chen, J.Y.; Wang, Y.L.; Wei, L.X.; Dong, J.H. Prognostic significance of mast cell count following curative resection for pancreatic ductal adenocarcinoma. Surgery 2011, 149, 576-584.
229. Chang, D.Z.; Ma, Y.; Ji, B.; Wang, H.; Deng, D.; Liu, Y.; Abbruzzese, J.L.; Liu, Y.J.; Logsdon, C.D.; Hwu, P. Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma. Clin. Cancer Res. 2011, 17, 7015-7023.
230. Demir, I.E.; Schorn, S.; Schremmer-Danninger, E.; Wang, K.; Kehl, T.; Giese, N.A.; Algul, H.; Friess, H.; Ceyhan, G.O. Perineural mast cells are specifically enriched in pancreatic neuritis and neuropathic pain in pancreatic cancer and chronic pancreatitis. PLoS ONE 2013, 8, 28.
231. Nguyen, J.; Luk, K.; Vang, D.; Soto, W.; Vincent, L.; Robiner, S.; Saavedra, R.; Li, Y.; Gupta, P.; Gupta, K. Morphine stimulates cancer progression and mast cell activation and impairs survival in transgenic mice with breast cancer. Br. J. Anaesth. 2014, 113, 26.
232. Pauling, L.; Itano, H.A. et al. Sickle cell anemia a molecular disease. Science 1949, 110, 543-548.
233. Gupta, M.; Msambichaka, L.; Ballas, S.K.; Gupta, K. Morphine for the treatment of pain in sickle cell disease. Sci. World J. 2015, 2015, 10.
234. Biedrzycki, O.J.; Bevan, D.; Lucas, S. Fatal overdose due to prescription fentanyl patches in a patient with sickle cell/β-thalassemia and acute chest syndrome: A case report and review of the literature. Am. J. Forensic Med. Pathol. 2009, 30, 188-190.
235. Murphy, M.; Close, J.; Lottenberg, R.; Rajasekhar, A. Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia. Am. J. Med. Sci. 2014, 347, 254-255.
236. Stankovic Stojanovic, K.; Thiolière, B.; Garandeau, E.; Lecomte, I.; Bachmeyer, C.; Lionnet, F. Chronic myeloid leukaemia and sickle cell disease: Could imatinib prevent vaso-occlusive crisis? Br. J. Haematol. 2011, 155, 271-272.
237. Afrin, L.B. Mast cell activation syndrome as a significant comorbidity in sickle cell disease. Am. J. Med. Sci. 2014, 348, 460-464.
238. Vang, D.; Paul, J.A.; Nguyen, J.; Tran, H.; Vincent, L.; Yasuda, D.; Zaveri, N.T.; Gupta, K. Small-molecule nociceptin receptor agonist ameliorates mast cell activation and pain in sickle mice. Haematologica 2015, 20, 128736.
239. Oliveira, S.M.; Drewes, C.C.; Silva, C.R.; Trevisan, G.; Boschen, S.L.; Moreira, C.G.; de Almeida Cabrini, D.; da Cunha, C.; Ferreira, J. Involvement of mast cells in a mouse model of postoperative pain. Eur. J. Pharmacol. 2011, 672, 88-95.
240. Yasuda, M.; Kido, K.; Ohtani, N.; Masaki, E. Mast cell stabilization promotes antinociceptive effects in a mouse model of postoperative pain. J. Pain Res. 2013, 6, 161-166.
241. Oliveira, S.M.; Silva, C.R.; Ferreira, J. Critical role of protease-activated receptor 2 activation by mast cell tryptase in the development of postoperative pain. Anesthesiology 2013, 118, 679-690.
242. Chen, Y.; Yang, C.; Wang, Z.J. Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxel-induced neuropathic pain. Neuroscience 2011, 193, 440-451.
243. Lynch, M.E.; Watson, C.P.N. The pharmacotherapy of chronic pain: A review. Pain Res. Manag. J. Can. Pain Soc. 2006, 11, 11-38.
244. De Filippis, D.; D’Amico, A.; Iuvone, T. Cannabinomimetic control of mast cell mediator release: New perspective in chronic inflammation. J. Neuroendocrinol. 2008, 1, 20-25.
245. Darmani, N.A.; Izzo, A.A.; Degenhardt, B.; Valenti, M.; Scaglione, G.; Capasso, R.; Sorrentini, I.; di Marzo, V. Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: Review of the available pre-clinical data, and first human studies. Neuropharmacology 2005, 48, 1154-1163.
246. Cobellis, L.; Castaldi, M.A.; Giordano, V.; Trabucco, E.; de Franciscis, P.; Torella, M.; Colacurci, N. Effectiveness of the association micronized N-palmitoylethanolamine (pea)-transpolydatin in the treatment of chronic pelvic pain related to endometriosis after laparoscopic assessment: A pilot study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2011, 158, 82-86.
247. Giugliano, E.; Cagnazzo, E.; Soave, I.; lo Monte, G.; Wenger, J.M.; Marci, R. The adjuvant use of N-palmitoylethanolamine and transpolydatin in the treatment of endometriotic pain. Eur. J. Obstet. Gynecol. Reprod. Biol. 2013, 168, 209-213.
248. Indraccolo, U.; Barbieri, F. Effect of palmitoylethanolamide-polydatin combination on chronic pelvic pain associated with endometriosis: Preliminary observations. Eur. J. Obstet. Gynecol. Reprod. Biol. 2010, 150, 76-79.
249. Di Marzo, V.; Bisogno, T.; de Petrocellis, L.; Melck, D.; Martin, B.R. Cannabimimetic fatty acid derivatives: The anandamide family and other endocannabinoids. Curr. Med. Chem. 1999, 6, 721-744.
250. Zhang, Q.H.; Zhou, Z.S.; Lu, G.S.; Song, B.; Guo, J.X. Melatonin improves bladder symptoms and may ameliorate bladder damage via increasing HO-1 in rats. Inflammation 2013, 36, 651-657.
251. Park, C.H.; Joo, Y.E.; Choi, S.K.; Rew, J.S.; Kim, S.J.; Lee, M.C. Activated mast cells infiltrate in close proximity to enteric nerves in diarrhea-predominant irritable bowel syndrome. J. Korean Med. Sci. 2003, 18, 204-210.